Evidence map›Paper›PMID 29606091›Full record

ArticleBMC infectious diseases2018

A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens.

Audrey Forson, Awewura Kwara, Samuel Kudzawu, Michael Omari, Jacob Otu, Florian Gehre, Bouke de Jong, Martin Antonio

Abstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Audrey ForsonUniversity of Ghana School of Medicine and Dentistry, Accra, Ghana. agforson@chs.edu.gh.
Awewura KwaraUniversity of Florida, College of Medicine, Gainesville, Florida, USA. Awewura.Kwara@medicine.ufl.edu.
Samuel KudzawuDepartment of Chest Diseases, Korle-Bu Teaching Hospital, Accra, Ghana.
Michael OmariDepartment of Chest Diseases, Korle-Bu Teaching Hospital, Accra, Ghana.
Jacob OtuMedical Research Council Unit, Banjul, The Gambia.
Florian GehreMedical Research Council Unit, Banjul, The Gambia.
Bouke de JongInstitute of Tropical Medicine, Antwerp, Belgium.
Martin AntonioMedical Research Council Unit, Banjul, The Gambia.

Funding

Training Program in Tuberculosis and HIV Research in GhanaD43TW010055 · FIC · UNIVERSITY OF FLORIDA · PI KWARA, AWEWURA JACOB · 2015 to 2019
$1.5M
European and Developing Countries Clinical Trials Partnership CB.07.41700.007FIC NIH HHS D43 TW010055NIH HHS TW010055
6 · The paper itself

Abstract

backgroundMycobacterium tuberculosis drug resistance is a major challenge to the use of standardized regimens for tuberculosis (TB) therapy, especially among previously treated patients. We aimed to investigate the frequency and pattern of drug resistance among previously treated patients with smear-positive pulmonary tuberculosis at the Korle-Bu Teaching Hospital Chest Clinic, Accra.

methodsThis was a cross-sectional survey of mycobacterial isolates from previously treated patients referred to the Chest Clinic Laboratory between October 2010 and October 2013. The Bactec MGIT 960 system for mycobactrerial culture and drug sensitivity testing (DST) was used for sputum culture of AFB smear-positive patients with relapse, treatment failure, failure of smear conversion, or default. Descriptive statistics were used to summarize patient characteristics, and frequency and patterns of drug resistance.

resultsA total of 112 isolates were studied out of 155 from previously treated patients. Twenty contaminated (12.9%) and 23 non-viable isolates (14.8%) were excluded. Of the 112 studied isolates, 53 (47.3%) were pan-sensitive to all first-line drugs tested Any resistance (mono and poly resistance) to isoniazid was found in 44 isolates (39.3%) and any resistance to streptomycin in 43 (38.4%). Thirty-one (27.7%) were MDR-TB. Eleven (35.5%) out of 31 MDR-TB isolates were pre-XDR. MDR-TB isolates were more likely than non-MDR isolates to have streptomycin and ethambutol resistance.

conclusionsThe main findings of this study were the high prevalence of MDR-TB and streptomycin resistance among previously treated TB patients, as well as a high prevalence of pre-XDR-TB among the MDR-TB patients, which suggest that first-line and second-line DST is essential to aid the design of effective regimens for these groups of patients in Ghana.

Indexed as

Drug Resistance, BacterialMycobacterium tuberculosisAdultAntitubercular AgentsCross-Sectional StudiesFemaleGhanaHumansMaleMicrobial Sensitivity TestsMiddle AgedPrevalencePublic HealthStandard of CareTertiary Care CentersTuberculosis, Multidrug-ResistantAntitubercular AgentsAnti-tuberculosis drug resistanceGhanaMDR-TBPreviously treatedPre-XDR-TB

Identifiers

PMID29606091
PMCPMC5879759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.